Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of miR-133b in diagnosing, forecasting and treating prostate cancer with osseous metastasis

1. The technology of mir-133b and prostate cancer, which is applied in the field of molecular biology, can solve the problems affecting the treatment effect of tumors and the absence of miR-133b.

Active Publication Date: 2017-12-19
THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, chemoradiotherapy drugs not only act on the tumor, but can also act on the healthy tissues around the tumor. Therefore, while killing the tumor, they also bring great side effects to the body, which ultimately affects the therapeutic effect on the tumor.
There is no report on the relationship between miR-133b and prostate cancer bone metastasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miR-133b in diagnosing, forecasting and treating prostate cancer with osseous metastasis
  • Application of miR-133b in diagnosing, forecasting and treating prostate cancer with osseous metastasis
  • Application of miR-133b in diagnosing, forecasting and treating prostate cancer with osseous metastasis

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0026] Experimental example 1. miR-133b is lowly expressed in prostate cancer tissue, and further lowly expressed in bone metastatic prostate cancer tissue

[0027] method:

[0028] RNA extraction, reverse transcription and real-time quantitative RT-PCR detection of miR-133b: extract the total RNA of all tissues and cells according to the instructions of RNA extraction reagent (Qiagen Company), and perform reverse transcription according to the instructions of Revert Aid First Strand cDNA SynthesisKit (Thermo Fisher Company) , using iQ SYBR Green reagent and CFX96 real-time quantitative PCR system (BIO-RAD company), using 2-ddCt relative quantitative method for fluorescence quantitative detection, using U6 as internal reference, to calculate the relative expression of miR-133b, miR-133b and The primers for U6 were designed, synthesized and purified by Guangzhou Ruibo Biotechnology Co., Ltd.

[0029] result:

[0030] The results of miR-133b expression in clinical specimens an...

experiment example 2

[0031] Experimental example 2. Low expression of miR-133b is associated with bone metastasis status and bone metastasis-free survival time in prostate cancer patients

[0032]According to the bone metastasis status of clinical specimens, the correlation analysis was carried out combined with the detected miR-133b expression level, and the patients were divided into miR-133b high expression group and miR-133b low expression group according to the median value of miR-133b expression level in prostate cancer tissues The analysis results are shown in Table 1, and the expression of miR-133b is correlated with the bone metastasis of prostate cancer.

[0033] Table 1. Correlation between miR-133b expression and bone metastasis status in prostate cancer patients

[0034]

[0035] According to the follow-up data of clinical specimens, the correlation between the expression of miR-133b and the 5-year overall survival time and 5-year bone metastasis-free survival time of prostate canc...

experiment example 3

[0036] Experimental example 3. Overexpression of miR-133b can inhibit the migration and invasion of prostate cancer in vitro

[0037] method:

[0038] The human miR-133b (miRBase number MIMAT0000770) gene was cloned into the pMSCV-puro retroviral vector (Clontech Company) to obtain the miR-133b expression plasmid, and the negative control plasmid or miR-133b expression plasmid were transfected into PC-3 In cells, C4-2B cells and VCap cells, Transwell chamber method was used to detect cell migration and invasion, and fluorescence quantitative detection was used to detect the expression of miR-133b.

[0039] result:

[0040] The constructed miR-133b expression plasmid was transfected into PC-3 cells, C4-2B cells and VCap cells, and the expression level of miR-133b image 3 As shown, the miR-133b expression plasmid can up-regulate the expression of miR-133b, which can be used for further study.

[0041] The results of cell migration and invasion experiments were as follows: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of miR-133b in diagnosing, forecasting and treating prostate cancer with osseous metastasis. The invention researches and finds that the miR-133b has low expression in prostate cancer and has lower expression in osseous metastasis of prostate cancer; a further research proves that the low expression of miR-133b is related to the osseous metastasis of prostate cancer and indicates shorter osseous metastasis-free survival period; besides, over-expression miR-133b is capable of in vitro restraining migration and invasion of prostate cancer and in vivo restraining osseous metastasis of prostate cancer; the miR-133b mimics also can in vitro restrain the osseous metastasis of prostate cancer; the above results prove that miR-133b can be used for preparing diagnostic reagent, forecasting reagent and osseous metastasis restraining drug for the prostate cancer with osseous metastasis.

Description

technical field [0001] The invention belongs to the field of molecular biology, and more specifically relates to the application of miR-133b in the diagnosis, prediction and treatment of prostate cancer bone metastasis. Background technique [0002] Prostate cancer (PCa) is one of the most common malignant tumors of the male genitourinary system. Cancer metastasis will greatly increase the mortality of prostate cancer patients. Bone is the second most common site of cancer metastasis. In my country, more than 80% of prostate cancer patients have had bone metastasis at the time of diagnosis, and bone metastasis is the leading cause of death in prostate cancer patients. Important reason, therefore, the early diagnosis of bone metastases is the key to clinical diagnosis and prognosis. In addition, for patients with advanced prostate cancer, the effect of surgical treatment is poor, and most of them adopt drug treatment. Depending on the condition, chemical drug therapy, extern...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68A61K45/00A61P35/00
CPCA61K45/00C12Q1/6886C12Q2600/158C12Q2600/178
Inventor 黄帅唐欲博瓦庆德彭新生郭远清
Owner THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com